First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

导出原文传递

翻译打印收藏纠错

作者： Arranz,R. ^[1] ; García-Noblejas,A. ^[2] ; Grande,C. ^[3] ; Cannata-Ortiz,J. ^[4] ; Sánchez,J.J. ^[5] ; García-Marco,J.-A. ^[6] ; Aláez,C. ^[7] ; Pérez-Calvo,J. ^[8] ; Martínez-Sánchez,P. ^[9] ; Sánchez-González,B. ^[10] ; Canales,M.-A. ^[11] ; Conde,E. ; Martín,A. ; Arranz,E. ; Terol,M.-J. ; Salar,A. ; Caballero,D.

作者单位： Hospital Universitario Puerta Hierro, Madrid, Spain ^[1] Clínica Moncloa, Madrid, Spain ^[2] Hospital del Mar, Barcelona, Spain ^[3] Hospital Universitario Marqués de Valdecilla, Madrid, Spain ^[4] Hospital Universitario La Paz, Madrid, Spain ^[5] Hospital Universitario Clínico de Salamanca, Salamanca, Spain ^[6] Hospital General Universitario Morales Meseguer, Murcia, Spain ^[7] Hospital Universitario Clínico de Valencia, Valencia, Spain ^[8] Hospital Univesitario La Princesa, Madrid, Spain ^[9] Clínica Universitaria de Navarra, Navarra, Spain ^[10] Hospital Univesitario 12 de Octubre, Madrid, Spain ^[11]

发布时间 2015-03-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Haematologica

2013年98卷10期

1563-1570页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

Haematologica

相似文献

Haematologica

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

Haematologica

相似文献

Haematologica

相关期刊

检索历史清除